The USP10/USP13 inhibitor spautin-1 has demonstrated broad anti-tumor activity across malignancies, including: Suppression of CD44 stabilization via USP10 inhibition, leading to impaired proliferation, stemness, and metastasis in breast Cancer, disruption of the GSK3β-ULK1 axis to inhibit autophagy and tumor progression in osteosarcoma91. Here, ULK1 is linked to breast carcinoma.